A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007724/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine
whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with
aTTP.
Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma
exchange (PE).
提供机构：
Vivli
创建时间：
2022-02-10
